Day: November 19, 2021

MILPITAS, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) — View, Inc. (Nasdaq: VIEW) (“View” or the “Company”) received on November 16, 2021, a standard notice from Nasdaq (the “Notice”) indicating that, as a result of not having timely filed its Quarterly Report on Form 10-Q for the period ended September 30, 2021, and because the Company has not yet filed its Form 10-Q for the period ended June 30, 2021 (the “Second Quarter Form 10-Q”), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission (the “SEC”). The Nasdaq notice has no immediate effect on the listing or trading of the Company’s common stock on the Nasdaq Global Market. The Notice provides that the Company must submit an update to its original plan...

MALVERN, Pa., Nov. 19, 2021 (GLOBE NEWSWIRE) — CubeSmart (NYSE: CUBE) (the “Company” or “CubeSmart”), the third-largest owner and operator of self-storage properties in the United States, announced today the closing of its previously announced underwritten public offering of 15,525,000 common shares of beneficial interest (“Common Shares”) at a public offering price of $51.00 per share, including 2,025,000 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional Common Shares. CubeSmart expects to use all of the net proceeds of the offering to fund a portion of the approximately $1.648 billion cash purchase price, plus the payoff of approximately $40.9 million of existing indebtedness of LAACO, Ltd. (“LAACO”), for its pending acquisition of LAACO, including its portfolio of 59 open and operating...

REDWOOD CITY, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare disease, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to a new employee. The independent members of the Board of Directors of Soleno approved the grant of a non-qualified stock option to purchase 75,000 shares of common stock to Michael Woloschak, Soleno’s new Vice President of Clinical Development, as an inducement for him entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $0.763 per share, which is equal to the closing price of Soleno’s common stock on the Nasdaq Stock Market on November 16, 2021, the...

BOSTON, Nov. 19, 2021 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced its participation in a fireside chat during the Piper Sandler 33rd Annual Virtual Healthcare conference being held from November 29 to December 2, 2021. John Celebi, president and chief executive officer and Erin Colgan, senior vice president of finance and administration of Sensei Biotherapeutics, participated in a pre-recorded fireside chat. The webcast will be made available beginning 10:00 am ET on Monday, November 22, 2021, on the Events & Presentations section of Sensei’s website at www.senseibio.com. A replay of the webcast will be on the website for approximately 90 days following the event. About Sensei BiotherapeuticsSensei...

CAMBRIDGE, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) — Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief Executive Officer, will be participating at the Piper Sandler 33rd Virtual Annual Healthcare Conference. Piper Sandler 33rd Virtual Annual Healthcare ConferenceDate: Tuesday, November 30 through Thursday, December 2, 2021 Vor’s pre-recorded presentation will be available on-demand from Piper Sandler beginning on Monday, November 22nd at 10:00 am ET and can also be accessed via the Investors section of the Company’s website at www.vorbio.com. About Vor BiopharmaVor Biopharma is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic...

TORONTO, Nov. 19, 2021 (GLOBE NEWSWIRE) — (TSX: SBN; SBN.PR.A) S Split Corp. (the “Fund”) has announced that the Fund will effect a partial redemption of its Preferred Shares (“Preferred Shares”) in order to maintain an equal number of Preferred Shares and Class A Shares (“Class A”) of the Fund outstanding. The partial redemption of the Preferred Shares is being made in connection with the automatic seven-year extension of the term of the Fund to November 30, 2028. Pursuant to the special retraction right granted to shareholders in connection with the extension of Fund, 168,373 Preferred Shares and 312,764 Class A Shares were surrendered for retraction. In order to maintain an equal number of Preferred Shares and Class A Shares, the Fund will redeem an aggregate of 144,391 Preferred Shares on a pro rata basis from all holders of...

MINNEAPOLIS, Nov. 19, 2021 (GLOBE NEWSWIRE) — Nuwellis, Inc. (NASDAQ: NUWE), today announced that, effective November 17, 2021, the independent directors approved an equity award under Nuwellis’ 2021 Inducement Plan, as a material inducement to an individual entering into employment with the company. The equity award was approved in accordance with NASDAQ Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan. In connection with entering into employment with Nuwellis, Inc., the individual, who was not previously an employee or director of Nuwellis, received an option to purchase an aggregate of 24,560 shares of the company’s common stock. The option award has an exercise price of $1.76 per share, the closing price of Nuwellis’ common stock on...

PHILADELPHIA, Nov. 19, 2021 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced it has granted an inducement award to a new employee. Passage Bio granted an option to purchase 130,000 shares of common stock to this employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price of $8.50 per share, which is equal to the closing price of Passage Bio’s common stock on November 15, 2021, the grant date of the option. The shares subject to the stock option will vest over four years, with 25 percent of the shares vesting on the one-year anniversary of the applicable grant date, and the remainder vesting in 36 equal...